Recofast® 250 Tablet: Each film-coated tablet contains Cefuroxime Axetil USP equivalent to Cefuroxime 250 mg.
Indication and Use
Tablet: Recofast tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Pharyngitis / Tonsillitis, Acute Bacterial Otitis Media, Acute Bacterial Maxillary Sinusitis, Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis, Uncomplicated Skin and Skin-Structure Infections, Uncomplicated Urinary Tract Infections, Uncomplicated Gonorrhea and Early Lyme Disease (erythema migrans).
Dosage and Administration
Tablet: May be administered without regard to meals.
Use in Pregnancy and Lactation
Pregnancy: The safety of Cefuroxime in the treatment of infections during pregnancy has not been established. Cefuroxime should only be used during pregnancy if the likely benefit outweighs the potential risk to the fetus and/or the mother. Lactation: Cefuroxime is excreted in breast milk, caution should be exercised when Cefuroxime is administered to a nursing mother.
Cefuroxime is generally well tolerated. General: Anaphylaxis, angioedema, pruritus, rash, serum sickness like reaction, and urticaria. Gastrointestinal: Pseudomembranous colitis. Hematological: Haemolytic anaemia, leukopenia, pancytopenia, thrombocytopenia and increased prothrombin time. Hepatic: Hepatic impairment including hepatitis and cholestasis, jaundice. Neurological: Seizure. Skin: Erythema multiforme, and toxic epidermal necrolysis. Urological: Renal dysfunction. Cephalosporin-class adverse reactions: Toxic nephropathy, aplastic anaemia, haemorrhage, increased creatinine, false-positive test for urinary glucose, increased alkaline phosphatase, neutropenia, elevated bilirubin, and agranulocytosis.
|Manufactured By||Rangs Pharma|